WHO reports 10.6 million tuberculosis cases as domestic funding rises despite global gaps
The WHO’s 2026 tuberculosis report estimates 1.13 million deaths in 2025, finds major gaps in diagnosis and treatment, and records stronger domestic funding.
Photo credit and license
Photo: Ajay Kumar Chaurasiya, Mycobacterium tuberculosis in Ziehl-Neelsen stained smear of sputum, CC BY-SA 4.0; archival image, December 2021 · Image source · License: Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0)An estimated 10.6 million people developed tuberculosis in 2025 and 1.13 million died from the disease, according to the World Health Organization’s Global Tuberculosis Report 2026, published on 12 November. The figures show progress in reducing the burden of the disease, but also a continuing public-health emergency. WHO compiled the assessment using information from 187 countries and areas representing more than 99% of global TB cases and population.
Governments increased domestic tuberculosis funding by 14% to US$5.6 billion between 2024 and 2025, according to WHO. That rise helped cushion a reduction in international support of a similar scale. The contrast highlights a difficult funding situation: national budgets are absorbing more responsibility while many health systems still need outside assistance to expand basic services.
The estimated annual death toll has fallen by 35% since 2015. WHO says this means the world finally met the first mortality milestone of its End TB Strategy, although five years late. The rate of new tuberculosis cases fell by only 14% over the same period, far short of the 50% reduction targeted for 2025. Declining numbers should therefore not be mistaken for success in reaching all international goals.
The burden is highly concentrated. Thirty countries accounted for 88% of people who developed tuberculosis in 2025. Regional trends differ sharply: the incidence rate declined by 42% in WHO’s European Region and by 30% in its African Region compared with 2015. In the Americas, by contrast, incidence rose for a fifth consecutive year and was 13% higher than in 2015.
Diagnosis and treatment remain major obstacles. Of the estimated 10.6 million people who developed the disease, around 8.4 million were diagnosed, leaving about 2.2 million undiagnosed or unreported. Only 59% of newly diagnosed patients received a WHO-recommended rapid diagnostic test. Among an estimated 370,000 people who developed rifampicin-resistant tuberculosis, just 42% accessed treatment.
WHO also warns that investment in new tools is insufficient. Global tuberculosis research funding was US$1.2 billion in 2023, less than a quarter of the US$5 billion annual target for 2027. The agency is urging governments and partners to protect financing, widen access to timely diagnosis and effective treatment, and accelerate development of vaccines and other prevention tools. The report’s central message is that a treatable disease still claims more than a million lives each year, even as some important indicators improve.